BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

3579

506690

UNICHEMLAB

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

UNICHEM LABORATORIES LTD performance

Today’s low

Today’s high

₹ 600.85 ₹ 616.30
₹ 602.40

52 week low

52 week high

₹ 501.00 ₹ 937.95
₹ 602.40

Open Price

₹ 616.30

Prev. Close

₹ 612.10

Volume (Shares)

14889.00

Total traded value

₹ 89.69

Upper Circuit

₹ 734.50

Lower Circuit

₹ 489.70

info

UNICHEM LABORATORIES LTD Share Price Update

As of the latest trading session, UNICHEM LABORATORIES LTD share price is currently at ₹ 602.4, which is down by ₹ -9.69 from its previous closing. Today, the stock has fluctuated between ₹ 600.85 and ₹ 616.30. Over the past year, UNICHEM LABORATORIES LTD has achieved a return of 6.34 %. In the last month alone, the return has been -11.86 %. Read More...

UNICHEM LABORATORIES LTD fundamentals


  • Market cap (Cr)

    4,241.24

  • P/E Ratio (TTM)

    -1,331.41

  • Beta

    0.83

  • Book Value / share

    335.24

  • Return on equity

    -1.55%

  • EPS (TTM)

    17.38

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    46.89

info icon alternate text
  • Market cap (Cr)

    4,246.87

  • P/E Ratio (TTM)

    -1,331.41

  • Beta

    0.77

  • Book Value / share

    335.24

  • Return on equity

    -1.55%

  • EPS (TTM)

    17.38

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    46.89

info icon alternate text

UNICHEM LABORATORIES LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 447.83
Operating Expense 404.96
Net Profit 46.89
Net Profit Margin (%) 10.47
Earnings Per Share (EPS) 6.66
EBITDA 93.14
Effective Tax Rate (%) 24.12
Particulars SEP 2024 (Values in Cr)
Revenue 436.88
Operating Expense 400.59
Net Profit 43.37
Net Profit Margin (%) 9.92
Earnings Per Share (EPS) 6.16
EBITDA 71.58
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 389.75
Operating Expense 377.04
Net Profit 21.48
Net Profit Margin (%) 5.51
Earnings Per Share (EPS) 3.05
EBITDA 48.97
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 399.24
Operating Expense 395.63
Net Profit -114.97
Net Profit Margin (%) -28.79
Earnings Per Share (EPS) -16.33
EBITDA -87.99
Effective Tax Rate (%) 0.00
Particulars DEC 2023 (Values in Cr)
Revenue 362.43
Operating Expense 371.08
Net Profit 69.30
Net Profit Margin (%) 19.12
Earnings Per Share (EPS) 9.85
EBITDA 97.27
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 1442.16
Operating Expense 1507.12
Net Profit -92.18
Net Profit Margin (%) -6.39
Earnings Per Share (EPS) -13.09
EBITDA 23.68
Effective Tax Rate (%) 0.00
Particulars MAR 2023 (Values in Cr)
Revenue 1072.43
Operating Expense 1280.70
Net Profit -299.70
Net Profit Margin (%) -27.94
Earnings Per Share (EPS) -42.57
EBITDA -163.72
Effective Tax Rate (%) -7.38
Particulars MAR 2022 (Values in Cr)
Revenue 942.93
Operating Expense 1071.74
Net Profit -55.43
Net Profit Margin (%) -5.87
Earnings Per Share (EPS) -7.87
EBITDA -1.49
Effective Tax Rate (%) 36.10
Particulars MAR 2021 (Values in Cr)
Revenue 1123.97
Operating Expense 1105.70
Net Profit 54.08
Net Profit Margin (%) 4.81
Earnings Per Share (EPS) 7.68
EBITDA 142.84
Effective Tax Rate (%) 17.60
Particulars MAR 2020 (Values in Cr)
Revenue 904.44
Operating Expense 1067.42
Net Profit -56.32
Net Profit Margin (%) -6.22
Earnings Per Share (EPS) -8.00
EBITDA 8.56
Effective Tax Rate (%) 11.75
Particulars MAR 2024 (Values in Cr)
Book Value / Share 335.54
ROE % -1.17
ROCE % 0.39
Total Debt to Total Equity 0.12
EBITDA Margin 7.26
Particulars MAR 2023 (Values in Cr)
Book Value / Share 345.89
ROE % -7.05
ROCE % -4.51
Total Debt to Total Equity 0.13
EBITDA Margin -1.29
Particulars MAR 2022 (Values in Cr)
Book Value / Share 371.90
ROE % 1.22
ROCE % 0.88
Total Debt to Total Equity 0.09
EBITDA Margin 9.16
Particulars MAR 2021 (Values in Cr)
Book Value / Share 363.16
ROE % 1.05
ROCE % 1.66
Total Debt to Total Equity 0.06
EBITDA Margin 10.51
Particulars MAR 2020 (Values in Cr)
Book Value / Share 359.54
ROE % -3.34
ROCE % -2.36
Total Debt to Total Equity 0.08
EBITDA Margin 1.40
Particulars MAR 2024 (Values in Cr)
Book Value / Share 325.91
ROE % -1.55
ROCE % -1.05
Total Debt to Total Equity 0.04
EBITDA Margin 5.52
Particulars MAR 2023 (Values in Cr)
Book Value / Share 338.65
ROE % -7.77
ROCE % -5.88
Total Debt to Total Equity 0.05
EBITDA Margin -4.88
Particulars MAR 2022 (Values in Cr)
Book Value / Share 379.52
ROE % -2.06
ROCE % -3.03
Total Debt to Total Equity 0.02
EBITDA Margin -0.16
Particulars MAR 2021 (Values in Cr)
Book Value / Share 383.11
ROE % 2.02
ROCE % 2.47
Total Debt to Total Equity 0.00
EBITDA Margin 12.71
Particulars MAR 2020 (Values in Cr)
Book Value / Share 375.99
ROE % -2.09
ROCE % -2.30
Total Debt to Total Equity 0.00
EBITDA Margin 0.95
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 154.32
Total Assets 3169.34
Total Liabilities 3169.34
Total Equity 2362.41
Share Outstanding 70405750
Price to Book Ratio 1.50
Return on Assets (%) -2.22
Return on Capital (%) -2.73
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 185.36
Total Assets 3193.04
Total Liabilities 3193.04
Total Equity 2435.30
Share Outstanding 70405750
Price to Book Ratio 0.85
Return on Assets (%) -6.33
Return on Capital (%) -7.4
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 114.10
Total Assets 3318.77
Total Liabilities 3318.77
Total Equity 2618.41
Share Outstanding 70405750
Price to Book Ratio 0.69
Return on Assets (%) 0.99
Return on Capital (%) 1.12
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 82.44
Total Assets 3125.71
Total Liabilities 3125.71
Total Equity 2556.83
Share Outstanding 70405750
Price to Book Ratio 0.81
Return on Assets (%) 1.09
Return on Capital (%) 1.29
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 233.81
Total Assets 3144.73
Total Liabilities 3144.73
Total Equity 2531.35
Share Outstanding 70405750
Price to Book Ratio 0.40
Return on Assets (%) -1.91
Return on Capital (%) -2.22
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 129.05
Total Assets 2863.69
Total Liabilities 2863.69
Total Equity 2294.62
Share Outstanding 70405750
Price to Book Ratio 1.50
Return on Assets (%) -3.21
Return on Capital (%) -3.91
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 157.27
Total Assets 2886.13
Total Liabilities 2886.13
Total Equity 2384.27
Share Outstanding 70405750
Price to Book Ratio 0.85
Return on Assets (%) -10.38
Return on Capital (%) -12.06
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 99.03
Total Assets 3122.08
Total Liabilities 3122.08
Total Equity 2672.04
Share Outstanding 70405750
Price to Book Ratio 0.69
Return on Assets (%) -1.77
Return on Capital (%) -1.98
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 57.58
Total Assets 3119.05
Total Liabilities 3119.05
Total Equity 2697.33
Share Outstanding 70405750
Price to Book Ratio 0.81
Return on Assets (%) 1.73
Return on Capital (%) 2.01
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 205.37
Total Assets 3025.13
Total Liabilities 3025.13
Total Equity 2647.18
Share Outstanding 70405750
Price to Book Ratio 0.40
Return on Assets (%) -1.86
Return on Capital (%) -2.12
Particulars MAR 2024 (Values in Cr)
Net Income -61.66
Cash from Operations 23.07
Cash from Investing 50.40
Cash from Financing -106.31
Net change in Cash -39.21
Free Cash Flow 45.62
Particulars MAR 2023 (Values in Cr)
Net Income -176.36
Cash from Operations -72.88
Cash from Investing 202.81
Cash from Financing -81.29
Net change in Cash 36.42
Free Cash Flow -28.56
Particulars MAR 2022 (Values in Cr)
Net Income 21.96
Cash from Operations -251.99
Cash from Investing 102.39
Cash from Financing 191.22
Net change in Cash 34.01
Free Cash Flow -124.99
Particulars MAR 2021 (Values in Cr)
Net Income 51.47
Cash from Operations 47.34
Cash from Investing -73.55
Cash from Financing -121.07
Net change in Cash -161.65
Free Cash Flow 335.15
Particulars MAR 2020 (Values in Cr)
Net Income -48.21
Cash from Operations 24.15
Cash from Investing -35.91
Cash from Financing -62.29
Net change in Cash -78.39
Free Cash Flow 410.30
Particulars MAR 2024 (Values in Cr)
Net Income -92.18
Cash from Operations -41.41
Cash from Investing 53.23
Cash from Financing -48.06
Net change in Cash -36.39
Free Cash Flow -21.04
Particulars MAR 2023 (Values in Cr)
Net Income -279.08
Cash from Operations -117.23
Cash from Investing 202.49
Cash from Financing -61.75
Net change in Cash 23.40
Free Cash Flow -75.18
Particulars MAR 2022 (Values in Cr)
Net Income -86.74
Cash from Operations -162.36
Cash from Investing 106.31
Cash from Financing 95.80
Net change in Cash 43.80
Free Cash Flow -35.80
Particulars MAR 2021 (Values in Cr)
Net Income 65.64
Cash from Operations -32.30
Cash from Investing -80.38
Cash from Financing -45.07
Net change in Cash -158.07
Free Cash Flow 253.56
Particulars MAR 2020 (Values in Cr)
Net Income -63.81
Cash from Operations -44.48
Cash from Investing -35.58
Cash from Financing -21.01
Net change in Cash -98.44
Free Cash Flow 334.38
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 19.95 2.02 284.31 34.11 / 77.70
BLISS GVS PHARMA LTD 122.65 16.07 1.27 1292.37 92.25 / 184.95
CIPLA LTD 1541.00 24.94 4.38 124457.39 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 272.25 22.56 2.76 801.26 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 22.35 6.30 284.31 34.11 / 77.70
AMRUTAJAN HEALTH LTD 679.10 39.81 6.59 1963.32 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8795.90 131.18 32.36 21989.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 122.65 15.93 1.26 1292.37 92.25 / 184.95

UNICHEM LABORATORIES LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
602.40 -1.58 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 621.00
  • 26 Days 637.90
  • 10 Days 624.20
  • 50 Days 656.20
  • 12 Days 625.70
  • 100 Days 675.90
  • 20 Days 632.80
  • 200 Days 661.40
616.58 PIVOT

First Support

604.77

First Resistance

623.92

Second Support

597.43

Second Resistance

635.73

Third Support

585.62

Third Resistance

643.07

RSI

43.04

ADX

9.66

MACD

-12.24

Williams % R

-48.57

Commodity Channel Index (CCI)

-40.37

Date

2025-04-29

Week

41214.00

Same Day

7688.00

Month

32632.00

1 Year

0.84

3 Year

0.94

Over 1 Month

-11.86%

down

Over 1 Year

6.34%

down

Over 3 Months

-14.57%

down

Over 3 Years

31.28%

down

Over 6 Months

-23.97%

down

Over 5 Years

33.17%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

UNICHEM LABORATORIES LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
17.47%
Promoter Holdings
70.22%
FII
0.98%
DII
11.32%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Ipca Laboratories Limited 3.7081011E7 (52.67%) Shareholding of Promoter and Promoter Group
Dr. Prakash Amrut Mody 8997952.0 (12.78%) Shareholding of Promoter and Promoter Group
Hdfc Small Cap Fund 5473134.0 (7.77%) Public Shareholding
Anita Prakash Mody 1323400.0 (1.88%) Shareholding of Promoter and Promoter Group
Supriya Prakash Mody 949936.0 (1.35%) Shareholding of Promoter and Promoter Group
Suparna Prakash Mody 949936.0 (1.35%) Shareholding of Promoter and Promoter Group
Dsp Healthcare Fund 843858.0 (1.2%) Public Shareholding
Dr. Prakash Amrut Mody - Suparna Mody Trust (promoter Trust ) 52016.0 (0.07%) Shareholding of Promoter and Promoter Group
Dr. Prakash Amrut Mody - Shwetambari Mody Trust (promoter Trust) 41283.0 (0.06%) Shareholding of Promoter and Promoter Group
Dr. Prakash Amrut Mody - Supriya Mody Trust (promoter Trust) 45052.0 (0.06%) Shareholding of Promoter and Promoter Group
The Hongkong And Shanghai Banking Corp.ltd. 500.0 (0.0%) Public Shareholding

News

Left Arrow
Right Arrow

UNICHEM LABORATORIES LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
01 Aug 2022 4.0 Final 03 Aug 2022 Equity shares
22 Jul 2021 4.0 Final 26 Jul 2021 Equity shares
20 Aug 2020 4.0 Final 24 Aug 2020 Equity shares
18 Jul 2019 4.0 Final 22 Jul 2019 Equity shares
19 Jul 2018 5.0 Final 23 Jul 2018 Equity shares
13 Jul 2017 3.0 Final 17 Jul 2017 Equity shares
17 Mar 2016 2.0 Interim 19 Mar 2016 Equity shares
02 Jul 2015 2.0 Final 06 Jul 2015 Equity shares
03 Jul 2014 4.0 Final 07 Jul 2014 Equity shares
23 Jan 2014 4.0 Interim 24 Jan 2014 Equity shares
11 Jul 2013 4.5 Final 15 Jul 2013 Equity shares
13 Sep 2012 3.0 Final 17 Sep 2012 Equity shares
14 Jul 2011 2.8 Final 18 Jul 2011 Equity shares
21 Oct 2010 3.0 Interim 22 Oct 2010 Equity shares
14 May 2010 7.0 Interim 2 17 May 2010 Equity shares
27 Oct 2009 3.0 Interim 28 Oct 2009 Equity shares
09 Jul 2009 5.0 Final 13 Jul 2009 Equity shares
29 Oct 2008 3.0 Interim 31 Oct 2008 Equity shares
10 Jul 2008 5.0 Final 14 Jul 2008 Equity shares
16 Mar 2007 5.0 Final 20 Mar 2007 Equity shares
13 Jul 2006 0.0 Final 16 Jul 2006 Equity shares
14 Jul 2005 0.0 Final 18 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
24 Mar 2004 16 Mar 2004 1:1
20 Apr 2000 04 Apr 2000 1:1
20 Apr 2000 03 Apr 2000 1:1
Ex-Date Old FV NEW FV Record Date
21 Oct 2010 5.0 2.0 22 Oct 2010
16 Mar 2004 10.0 5.0 24 Mar 2004
16 Mar 2004 10.0 5.0 24 Mar 2004
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
01 Aug 2022 4.0 Final 03 Aug 2022 Equity shares
22 Jul 2021 4.0 Final 26 Jul 2021 Equity shares
20 Aug 2020 4.0 Final 24 Aug 2020 Equity shares
18 Jul 2019 4.0 Final 22 Jul 2019 Equity shares
19 Jul 2018 5.0 Final 23 Jul 2018 Equity shares
13 Jul 2017 3.0 Final 17 Jul 2017 Equity shares
17 Mar 2016 2.0 Interim 19 Mar 2016 Equity shares
02 Jul 2015 2.0 Final 06 Jul 2015 Equity shares
03 Jul 2014 4.0 Final 07 Jul 2014 Equity shares
23 Jan 2014 4.0 Interim 24 Jan 2014 Equity shares
11 Jul 2013 4.5 Final 15 Jul 2013 Equity shares
13 Sep 2012 3.0 Final 17 Sep 2012 Equity shares
14 Jul 2011 2.8 Final 18 Jul 2011 Equity shares
21 Oct 2010 3.0 Interim 22 Oct 2010 Equity shares
14 May 2010 7.0 Interim 2 17 May 2010 Equity shares
27 Oct 2009 3.0 Interim 28 Oct 2009 Equity shares
09 Jul 2009 5.0 Final 13 Jul 2009 Equity shares
29 Oct 2008 3.0 Interim 31 Oct 2008 Equity shares
10 Jul 2008 5.0 Final 14 Jul 2008 Equity shares
16 Mar 2007 5.0 Final 20 Mar 2007 Equity shares
13 Jul 2006 0.0 Final 16 Jul 2006 Equity shares
14 Jul 2005 0.0 Final 18 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
24 Mar 2004 16 Mar 2004 1:1
20 Apr 2000 04 Apr 2000 1:1
20 Apr 2000 03 Apr 2000 1:1
Ex-Date Old FV NEW FV Record Date
21 Oct 2010 5.0 2.0 22 Oct 2010
16 Mar 2004 10.0 5.0 24 Mar 2004
16 Mar 2004 10.0 5.0 24 Mar 2004

UNICHEM LABORATORIES LTD Share Price

Unichem Laboratories Limited is an India-based pharmaceutical company, which manufactures active pharmaceutical ingredients. The company operates through four divisions, namely Unichem Pharma Division, Unichem Specialities Division, Unisearch Division and Neu-Foreva Division. The company is headquartered in Mumbai with five manufacturing facilities located at Roha in Maharashtra, Goa, Ghaziabad in Uttar Pradesh, Pithampur in Madhya Pradesh and Baddi in Himachal Pradesh.

The company's facilities enjoy credible certifications, the Goa plant was approved by UK MHRA, MCC (South Africa), WHO (Geneva) and TGA (Australia). The Baddi plant was approved by UK MHRA and MCC (South Africa). The company received ISO 9001:2000 for all their plants and corporate office. Also, they received ISO 14001:2004 certificates for their formulation plants located at Goa, Ghaziabad and Baddi and the corporate office at Mumbai.

Unichem Laboratories Limited was incorporated in 1962. The company was formed by Dr. Prakash Amrut Mody to take over a proprietary business set up in 1944 in Mumbai. They made a foreign collaboration with UCB for bulk drugs and set up first formulation plant at Jogeshwari. In the year 1963, they made a tie up with Uni Sankyo Co-Marketing formulations.

In the year 1968, the company set up formulations plant Ghaziabad and in the year 1976, they set up a fine chemicals unit at Roha. In the year 1984, the company entered an agreement with Upjohn and set up Unisearch Ltd. Also, they entered into the anti-biotic segment and launched Ampoxin, an Ampicillin & Claxacillin combination during the year.

In the year 1987, the company entered the Animal Health Care business. In the year 1996, Unichem Exports Ltd and Unisearch Ltd were merged with the Unichem Laboratories Ltd. In the year 1997, the company set up new corporate office at Mumbai and in May 1997, the company's state-of-the-art formulation plant at Bardez, Goa was successfully commissioned and commercial production was started. In the year 1998, their plant at Baddi, Himachal Pradesh for Antibiotics was completed.

In the year 1999, the company set up modern multipurpose bulk drug plant at Roha. In April 1, 1999, the company launched their new Division, namely Foreva catering to Women's Healthcare. In February 2000, they set up their Molecular Generic Division, which launched 23 new products in the two months of the financial year 1999-2000. Also, the company purchased two brands, namely Emcredil and Candizole-T for a total cost of Rs 132 lakh during the financial year 1999-2000.

In the year 2001, the company set up new R&D centre at Mumbai. Also, they set up new Biosciences R&D centre at Bangalore in association with Indian Institute of Sciences for research work in Bio-technology. In April 2002, the company established a joint venture company with Bioglan Generics Ltd, namely Niche Generics Ltd with 60% stake.

During the year 2002-03, they divested their animal healthcare division. They upgraded the Ghaziabad plant with an investment of Rs 250 million. Also, they started a representative office in Kiev, Ukraine. In March 2003, Unichem SA Pty Ltd became a subsidiary of the company. In the year 2004, they restructured Unisearch and launched Unisearch CD Division.

In the year 2005, the company set up a New Pharma Technology Development Center at Goa. Also, they acquired API manufacturing unit at Pithampur. Further, the company set up their second formulations plant at Baddi and production commenced in April 2005. In May 2005 the company disposed off their old factory at Jogeshwari (West) Mumbai for a consideration of Rs 136.50 million. During the year 2005-06, the company set up a wholly owned subsidiary Unichem Pharmaceuticals (USA) Inc, in USA.

During the year 2006-07, the company started Unichem Specialities Division and launched 11 new products in various therapeutic segments. In December 20006, they acquired the remaining 60% stake in Niche Generics Ltd of UK and thus Niche Generics Ltd became a wholly owned subsidiary company.

During the year 2007-08, the company launched Unikare Division, which caters to Dermatology and Allied therapies. They also launched 27 new products in various therapeutic segments during the year. The company has initiated projects including setting up of a Formulation Plant at Sikkim and the expansion of their existing formulation facility at Baddi in Himachal Pradesh.

The Company launched new division focusing on nephrology in cardiology segment during 2009. It commissioned new formulation plant at Sikkim, which is a solid oral dosage form facility, commissioned a new unit at Baddi for manufacturing all dosage forms of Cephalosporin and launched 19 new products during 2010.

In 2011, the Company launched 22 new brands in various in various therapeutic segments. 4 new brands were launched in Cardiac Care, 3 in Dermatology and 2 in Neuropsychiatry amongst others.

During year 2011-12, a Scheme of Arrangement between AVM Capital Services Private Limited, Chevy Capital Services Private Limited, PM Capital Services Private Limited, Pranit Trading Private Limited and Viramrut Trading Private Limited and Unichem Laboratories Limited was approved by the Hon'ble High Court vide Order dated July 12, 2012 and as a result, the Scheme became effective on August 6, 2012.

The Company incorporated a new subsidiary in Ireland taking the total number of subsidiaries to 5 in March, 2012. In 2013, the Company completed dosage formulations facility at SEZ Pithampur and made agreement to sell the same to Mylan Laboratories Limited. During the year 2015, Synchron Research Private Limited became an Associate of Company.

The Company, in December 2017, transferred its business of manufacture, sale, marketing and distribution of domestic formulations in India and Nepal, and the manufacturing facility at Sikkim together with all assets and liabilities through slump sale on a going concern basis, to Torrent Pharmaceuticals Limited on mutually agreed terms and conditions.

In November 2018, the Company had made a strategic investment in two Hyderabad based Active Pharmaceutical Ingredients (APIs) manufacturing company namely Optimus Drugs Private Limited (ODPL) and Optrix Laboratories Limited for a total consideration of Rs 12,000.62 Lakhs by acquiring 19.99% of the issued and paid-up share capital of each of the said companies. Optrix was later merged into ODPL with no change in the overall shareholdings of the Company in the merged entity. Unichem held 19.99% of the equity share capital of ODPL.

The Company incorporated a Wholly Owned Subsidiary in China on June 27, 2019 under the name 'Younikaimo Pharmaceutical (Shanghai) Private Limited' in 2020.

During the year 2023-24, Ipca Laboratories Limited acquired 2,35,01,440 fully paid-up equity shares of Rs 2/- each, constituting 33.38% of the fully diluted voting share capital of the Company from Dr. Prakash A. Mody, Promoter & Director. On 21st September, 2023, Ipca Laboratories Limited further acquired an aggregate 1,35,79,571 equity shares at Rs 440 per equity share pursuant to the open offer made by Ipca Laboratories Limited to the public shareholders of the Company in terms of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Consequently, the aggregate holding of Ipca Laboratories Limited in the Company as on 31st March, 2024 stood 3,70,81,011 equity shares of the Company representing 52.67% of the total paid-up equity share capital of the Company. Thus, Ipca Laboratories Limited acquired majority control over the Company and accordingly, the Company became a subsidiary of Ipca Laboratories Limited.

Parent organization Indian Private
NSE symbol UNICHEMLAB
Founded 1962
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Unichem Laboratories Ltd?

Answer Field

The share price of Unichem Laboratories Ltd for NSE is ₹ 602.4 and for BSE is ₹ 603.2.

What is the Market Cap of Unichem Laboratories Ltd?

Answer Field

The market cap of Unichem Laboratories Ltd for NSE is ₹ 42,41.24 Cr. and for BSE is ₹ 42,46.87 Cr. as of now.

What is the 52 Week High and Low of Unichem Laboratories Ltd?

Answer Field

The 52 Week High and Low of Unichem Laboratories Ltd for NSE is ₹ 937.95 and ₹ 501.00 and for BSE is ₹ 949.85 and ₹ 507.20.

How to Buy Unichem Laboratories Ltd share?

Answer Field

You can trade in Unichem Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Unichem Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been 6.34%.

What is the Current Share Price of Unichem Laboratories Ltd?

Answer Field

Unichem Laboratories Ltd share price is for NSE ₹ 602.4 & for BSE ₹ 603.2 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Unichem Laboratories Ltd Share?

Answer Field

The market cap of Unichem Laboratories Ltd for NSE ₹ 42,41.24 & for BSE ₹ 42,46.87 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Unichem Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Unichem Laboratories Ltd share is -1331.41.

What is the PB ratio of Unichem Laboratories Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Unichem Laboratories Ltd share is 335.24.

How to Buy Unichem Laboratories Ltd Share?

Answer Field

You can trade in Unichem Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Unichem Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Unichem Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Unichem Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|